Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00308087. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
Study identification
- NCT ID
- NCT00308087
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- May 31, 2009
- Completion
- May 31, 2009
- Last update posted
- Dec 26, 2013
2006 – 2009
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35234 | — |
| Not listed | Huntsville | Alabama | 35805 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Montebello | California | 90640 | — |
| Not listed | Pleasant Hill | California | 94523 | — |
| Not listed | Gainesville | Florida | 32610-0254 | — |
| Not listed | Jacksonville | Florida | 32207 | — |
| Not listed | Ocala | Florida | 34474 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Elk Grove Village | Illinois | 60007 | — |
| Not listed | Springfield | Illinois | 62703 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | New Albany | Indiana | 47150 | — |
| Not listed | Duluth | Minnesota | 55805-1984 | — |
| Not listed | Fresh Meadows | New York | 11365 | — |
| Not listed | New York | New York | 10019 | — |
| Not listed | Columbus | Ohio | 43235 | — |
| Not listed | Hershey | Pennsylvania | 17033-0850 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00308087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 26, 2013 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00308087 live on ClinicalTrials.gov.